Black Diamond Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Black Diamond Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q3 2024.
  • Black Diamond Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.99M, a 27.6% decline year-over-year.
  • Black Diamond Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $10.5M, a 4.07% decline year-over-year.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9.6M, a 21.3% decline from 2022.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $12.2M, a 13.1% decline from 2021.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $14M, a 80.8% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $10.5M $1.99M -$759K -27.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $11.3M $5.29M +$2.64M +99.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $8.65M $1.71M -$958K -35.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $9.6M $1.54M -$1.37M -47.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 $11M $2.75M +$87K +3.27% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $10.9M $2.65M -$606K -18.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $11.5M $2.67M -$704K -20.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $12.2M $2.91M -$470K -13.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 $12.7M $2.66M -$345K -11.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $13M $3.25M -$1.31M -28.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $14.3M $3.38M +$281K +9.08% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $14M $3.38M +$906K +36.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $13.1M $3.01M +$1.01M +50.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $12.1M $4.56M +$3.14M +221% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $8.98M $3.09M +$1.22M +64.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $7.77M $2.47M -$40K -1.59% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 $7.81M $2M +$1.15M +135% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $6.66M $1.42M +$1.23M +639% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $5.43M $1.88M +$1.79M +1963% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $3.64M $2.51M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $850K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $192K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $91K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.